Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey

Jakko Van Ingen , Stefano Aliberti , Claire Andrejak (1, 2) , James D. Chalmers , Luigi R. Codecasa , Charles L. Daley , Naoki Hasegawa , David E. Griffith , Wouter Hoefsloot (3) , Gwen Huitt , Julie Jarand , Byung Woo Jhun , Michael R. Loebinger , Theodore K. Marras , Kozo Morimoto , Eva Polverino , Felix C. Ringshausen , Miguel Santin (4) , Rachel Thomson (5) , Dirk Wagner , Richard J. Wallace , Kevin L. Winthrop , Jae-Joon Yim , Nontuberculous Mycobacteria Networ

1 CHU Amiens-Picardie
2 AGIR - Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
3 Radboud University [Nijmegen]
4 University of Barcelona
5 CIRCY, University of Sussex

Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastroin-testinal upset. These opinions can provide assistance in individual patient management decisions.

Domaines: Sciences du Vivant [q-bio]

Jakko Van Ingen, Stefano Aliberti, Claire Andrejak, James D. Chalmers, Luigi R. Codecasa, et al.. Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clinical Infectious Diseases, 2021, 73 (1), pp.E256-E259. ⟨10.1093/cid/ciaa1361⟩. ⟨hal-03591318⟩